Maze Therapeutics’ (MAZE) Buy Rating Reaffirmed at Guggenheim

Maze Therapeutics (NASDAQ:MAZE)‘s stock had its “buy” rating reissued by analysts at Guggenheim in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $19.00 target price on the stock. Guggenheim’s price target indicates a potential upside of 91.73% from the stock’s previous close.

Several other research analysts have also recently weighed in on the company. Leerink Partners assumed coverage on Maze Therapeutics in a research note on Tuesday, February 25th. They issued an “outperform” rating and a $28.00 price target for the company. Leerink Partnrs raised Maze Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 25th. TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 25th. Finally, JPMorgan Chase & Co. started coverage on shares of Maze Therapeutics in a research report on Tuesday, February 25th. They set an “overweight” rating and a $30.00 price objective on the stock. Three equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $25.67.

Maze Therapeutics Price Performance

MAZE stock traded up $0.01 during trading on Wednesday, hitting $9.91. 52,512 shares of the stock traded hands, compared to its average volume of 304,665. Maze Therapeutics has a 1 year low of $9.49 and a 1 year high of $17.00.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Monday, March 31st. The company reported ($18.32) EPS for the quarter, missing analysts’ consensus estimates of ($7.60) by ($10.72).

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.